New injection could ease sleep apnea in people with obesity
NCT ID NCT06994650
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tests an investigational drug called HRS9531 in 140 adults with moderate-to-severe obstructive sleep apnea and obesity who already use a breathing machine (PAP therapy). The goal is to see if the drug can reduce breathing pauses during sleep and improve symptoms over 52 weeks. Participants will receive either the drug or a placebo injection, and must be willing to pause PAP therapy for sleep tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBJECTS WITH MODERATE-TO-SEVERE OSA AND OBESITY WHO ARE ON PAP THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact
Conditions
Explore the condition pages connected to this study.